Congenital Adrenal Hyperplasias Presenting in the Newborn and Young Infant

Introduction

The most common and representative example of the congenital adrenal hyperplasia (CAH) group of disorders (≥90%) is the 21-hydroxylase deficiency (CYP21A2-D). Less frequent types of CAH are 11β-hydroxylase deficiency (CYP11B1-D, up to 8% cases), 17α-hydroxylase/17–20 lyase deficiency (CYP17A1-D), 3β-hydroxysteroid dehydrogenase deficiency (HDS3B2-D), P450 oxidoreductase deficiency (POR-D), P450 cytochrome side-chain cleavage deficiency (CYP11A1-D), and StAR deficiency (StAR-D). In CYP21A2-D and CYP11B1-D, only adrenal steroidogenesis is affected, whereas a defect in the other enzymes also involves gonadal steroid biosynthesis (1, 2) (Table 1).

TABLE 1

Table 1. A summary of genetic, early clinical, biochemical features, and therapy of the CAH deficiencies presenting in the 1st year of life [modified by (1)].

Steroid Acute Regulatory Protein deficiency—Lipoid CAH (StAR-D)

Epidemiology/Genetics

StAR-D is uncommon in most populations, but it is relatively more frequent in East Asian (3, 4), Arab (5), and Swiss (6) populations because of the occurrence of the p.Q258X, p.R182L/p.R182I, and p.L260P founder mutations, respectively. To date, ~85 pathogenic variants of the StAR gene have been reported (www.hgmd.cf.ac.uk) (Table 1).

Essential Biochemistry

StAR is a fundamental actor in steroidogenesis, transferring cholesterol from the outer (OMM) to the inner mitochondrial membrane (IMM), where CYP11A1 can convert cholesterol to pregnenolone (Preg) (Figure 1A). The complex pathophysiology of StAR-D is explained by the “two-hit disease model” (5): the major part of steroidogenesis is StAR dependent, and its deficit, the first hit, activates the ACTH axis and de novo cholesterol biosynthesis; the consequent steroid underproduction due to the toxic effects of accumulating cholesterol follows as the second hit. The impairment of testicular steroidogenesis, which is active earlier than the ovarian one, is the first consequence of StAR-D with fetal androgen deficiency, causing undervirilization in 46,XY genetic newborns (7). Fetal adrenal androgen deficiency also leads to reduction of maternal estriol (E3) levels, prenatally measurable in a maternal urine sample (8). As placental steroidogenesis is not StAR dependent, Prog production is able to maintain pregnancy to term.

FIGURE 1

Figure 1. (A) Adrenal and gonadal steroidogenesis (Classic and Backdoor pathways). StAR, steroidogenic acute regulatory protein; OMM, outer microsomal membrane; IMM, inner microsomal membrane; DHEA/DHEA-S, Dehydroepiandrosterone/D-Sulfate; DOC, Deoxycorticosterone; 17OH-DHProg, 5-Pregnan-17-ol-3,20-dione (diol); 17OH-ALLO, 17OH-allopregnanolone; CYP11A1, cholesterol side-chain cleavage enzyme; CYP17A1, 17-hydroxylase/17, 20 lyase; SULT2A1, dehydroepiandrosterone (DHEA) sulfotransferase; POR, P450 oxidoreductase; CYP21A2, 21-hydroxylase; HSD3B2, 3-hydroxysteroid dehydrogenase; CYP11B1, 11-hydroxylase; CYP11B2, aldosterone synthase; HSD17B3, 17-hydroxysteroid dehydrogenase type 3; SRD5A1, 5-reductase type 1; SRD5A2, 5-reductase type 2; Fdx/ FdR, ferredoxin/ferredoxin reductase; CYB5A, cytochrome b5. (B) The metabolic pathways of classic and non-classic androgens. The gray box indicates 11-oxygenated C19 steroids. The red, orange, and yellow boxes depict steroids with strong, mild, and weak androgenic activities, respectively. HSD17B3, 17-hydroxysteroid dehydrogenase type 3; HSD3B2, 3-hydroxysteroid dehydrogenase type 2; AKR1C3, aldo-keto reductase family 1 member C3; CYP11B1, cytochrome P450 11B1; HSD11B1, 11-hydroxysteroid dehydrogenase type 1; HSD11B2, 11-hydroxysteroid dehydrogenase type 2; HSD17B2, 17-hydroxysteroid dehydrogenase type 2; SRD5A1, 5-reductase type 1; SRD5A2, 5-reductase type 2; Pregn, pregnenolone; 17-OHpregn, 17-OHpregnenolone; DHEA-S, dehydroepiandrosterone-sulfate; SULT2A1, sulfotransferase family 2A member 1; DHEA, dehydroepiandrosterone; Prog, progesterone; 17-OHP, 17-OH-progesterone; D4-A, androstenedione; 11-OHD4A, 11-hydroxyandrostenedione; 11-KD4A, 11-ketoandrostenedione; 11-OHT, 11-hydroxytestosterone; 11-KT, 11-ketotestosterone; 5-dione, 5-androstanedione; DHT, dihydrotestosterone; 11-OHDHT, 11-hydroxydihydrotestosterone; 11-KDHT, 11-ketodihydrotestosterone.

Clinical Presentation and Diagnosis

In its most severe form, the affected newborns cannot produce significant amounts of any steroid (9, 10). They show high ACTH levels, increased plasma renin activity, and engorged adrenal glands containing excessive amounts of cholesterol and its derivatives (5) (Table 1). Classic patients have severe salt loss within the 1st months of life and female external genitalia, irrespective of chromosomal sex (11). In 46,XY babies, Sertoli cells stay intact and the anti-Mullerian hormone (AMH) inhibits the development of Mullerian structures. The hydrosaline balance is controlled prenatally by the placenta, but mineralocorticoid (MC) deficiency emerges within 2–3 weeks due to progressive cellular destruction and some remaining StAR-independent MC biosynthesis. “As the ovary is steroidogenically quiescent until puberty, it is protected from cellular damage until steroidogenesis begins” (12, 13).

P450 Cytochrome Side-Chain Cleavage Deficiency (CYP11A1-D)

Epidemiology/Genetics

CYP11A1-D is an even rarer defect than StAR-D, and it is caused by pathogenic variants of the CYP11A1 gene (14). To date, 40 patients and 25 variations of CYP11A1 have been reported. Almost all cases are homozygous or compound heterozygous (15). Autosomal dominant inheritance has also been proposed in a few cases (16, 17).

Essential Biochemistry/Pathophysiology

CYP11A1 catalyzes the conversion of cholesterol to Preg in three consecutive rate-limiting steps: 20α-hydroxylation, 22R-hydroxylation, and cleavage of the C20–C22 carbon side chain (18) (Figure 1A). CYP11A1-D determines defects in all three steroidogenic pathways: MC, glucocorticoid (GC) in the adrenals, and androgen (Andr) in the adrenals and gonads. Complete CYP11A1-D was considered incompatible with term pregnancies due to impaired placental progesterone and maternal estrone (E1) production; the reason why some cases survived pregnancy is still not completely clear (19–22). The expression of CYP11A1-D occurs early in fetal testes, causing defective gonadal steroidogenesis that dramatically impairs virilization of 46,XY fetuses (23).

Clinical Presentation and Diagnosis

In newborns, the most severe presentation is characterized by early adrenal insufficiency with salt wasting (SW), hypoglycemia, skin hyperpigmentation, and complete feminization of external genitalia, regardless of sex chromosomes. The 46,XY newborns show normal or hypoplastic derivatives of Wolffian duct and small testes, whereas derivatives of Mullerian duct are absent (11). Histology of the testes reveals immature tissue without germ cells (20). A phenotype with neonatal and transient adrenal insufficiency, life-threatening failure to thrive, and normal male external genitalia in 46,XY patients was reported in 2018 in three heterozygous related cases (17). One case of mid-shaft hypospadias and cryptorchidism at birth and another with penoscrotal hypospadias associated with late-onset adrenal insufficiency (9 and 2 years of age, respectively) were reported in 2009 (24) and 2012 (25). In newborns, blood tests showed severe hyponatremia, hyperkalemia, extremely elevated levels of ACTH, and renin activity with low or inappropriately normal levels of cortisol and aldosterone. Unlike most classic lipoid-CAH (26), adrenal glands are reduced in size in CYP11A1-D (27).

3β-Hydroxysteroid Dehydrogenase Deficiency (HSD3B2-D)

Epidemiology/Genetics

HSD3B2-D is a very rare form of CAH (estimated incidence of < 1/1,000,000 live births) (18, 28) caused by mutations in the HSD3B2 gene (Table 1) that encode the 3β-HSD2 enzyme. It is involved in all three steroidogenic pathways: aldosterone, cortisol, and androgen precursors in the adrenals and testosterone (T) in the gonads (18). Loss-of-function mutations (<5% residual enzyme activity) predict the neonatal SW phenotype. Mutations causing >5% 3β-HSD2 activity lead to residual MC production without SW (29).

Essential Biochemistry/Pathophysiology

3β-HSD2 enzyme converts Δ5-3β-hydroxysteroids into corresponding Δ4-3-keto isomers, Preg to Prog, 17α-hydroxypregnenolone (17OHPreg) to 17α-hydroxyprogesterone (17OHP), dehydroepiandrosterone (DHEA) to Δ4-androstenedione (Δ4A), and androstenediol to T. In SW HSD3B2-D, glucocorticoid and mineralocorticoid are impaired causing hyponatremia, hyperkalemia, and elevated renin concentrations in both sexes. In females, 3β-HSD2 deficiency prevents the flooding of 17OHP and Δ4A to backdoor and 11-oxyandrogen production pathways (see CYP21A2-D) (Figures 1A,B); in males, T production is impaired during the critical period of sexual differentiation and dihydrotestosterone (DHT) production is subsequently reduced by classical and backdoor pathways (30).

Clinical Presentation and Diagnosis

Historically, the clinical presentation of HSD3B2-D at birth is described as the “classic form,” with or without SW, hypoglycemia, ambiguous genitalia, and hypogonadism in both sexes. Recent studies have shown that HSD3B2-D rarely causes ambiguous genitalia in females and thus the affected 46,XX newborns may present mild clitoromegaly only, whereas affected 46,XY newborns may present some degree of external genitalia undervirilization or isolated hypospadias, which need to be graded based on reliable tools (EGS) (31), (EMS) (32), (Prader) (33). The frequency of HSD3B2-D could be underestimated in females without SW and normal genitalia. However, in countries with NSP for 21-OHD, it is possible that newborns with HSD3B2-D may show false positivity for elevated levels of 17-OHP (34–37). The principal diagnostic test for HSD3B2-D is the serum measurement of 17-OHpreg, cortisol, Δ4A, 17-OHP, and DHEA (basal or post-ACTH stimulation) (28) with a predominance of Δ5 steroids (i.e., Preg, 17OHPreg, and DHEA) over Δ4 steroids (Prog, 17OHP, and Δ4A). Guran et al. (30) reported that high baseline 17OHpreg-to-cortisol ratio and low 11-oxyandrogen concentrations by LC/MSMS provide an unequivocal biochemical diagnosis of patients with HSD3B2-D. Although urinary steroid profiling is considered to be similarly accurate and less invasive for diagnosis (38), it can be notoriously difficult to diagnose HSD3B2-D on urine sample alone due to the naturally high levels of 3βOH5ene steroids in neonates.

17α-Hydroxylase/17,20 Lyase Deficiency (CYP17A1-D)

Epidemiology/Genetics

The incidence of CYP17A1-D is estimated to be about 1 in 50,000 (39). The disease prevalence is higher in certain countries such as the Netherlands (Friedlanders), Brazil, China, and Japan, where it is the second leading cause of CAH. This is attributable to loss-of-function mutations in the CYP17A1 gene (40) (Table 1). Over 100 mutations in the CYP17A1 gene are known, mostly resulting in complete loss of enzymatic activities of both 17-hydroxylase and 17–20 lyase (39). Researchers have also reported partial loss of enzymatic activity and loss of either hydroxylase or lyase activity alone (41).

Essential Biochemistry

CYP17A1 mediates three major transformations in cortisol and sex steroid biosynthesis. In particular, 17-hydroxylase mediates the synthesis of 17-Preg from Preg and 17OHP from Prog, whereas 17–20 lyase controls the production of DHEA from 17OHPreg. This latter step is of paramount importance as DHEA is the progenitor of steroid sex hormones (Figure 1A). The biochemical markers used to diagnose CYP17A1-D are shown in Table 1.

Clinical Presentation and Diagnosis

In 46,XX patients, external genitalia are normal on the neonatal exam as are the internal one to ultrasound (US). They may have no complaints before the typical age of puberty when the deficiency in sex hormones becomes apparent and they may develop hypertension or hypokalemia and high gonadotropin levels (hypergonadotropic hypogonadism).

In 46,XY patients, the presentation is typically under masculinization and can range from phenotypic female to ambiguous or small male genitalia (41). On physical examination, they may have a blind pouch instead of a vagina with a lack of internal female genitalia. The testes are undescended or located in the inguinal canal on imaging studies. Early diagnosis and treatment allow for the prevention of morbidity associated with hypertension, electrolyte abnormalities, and impairment of sexual development. As NSP identifies classic CYP21A2-D but does not detect CYP17A1-D, provider awareness and consideration of this condition are imperative for appropriate diagnosis.

21-Hydroxylase Deficiency (CYP21A2-D)

Epidemiology/Genetics

The most common form of CAH is represented by CYP21A2-D (90% cases). The severity of the enzymatic deficiency determines three clinical forms: SW (<1% enzyme activity), simple virilizing (SV; 1–2%), and non-classical (NC; 20–60%). The incidence of classic forms (SW and SV) ranges between 1 in 13,000 and 1 in 15,000 live births (42): in most populations, the frequency of heterozygous carriers is 1 in 60. CYP21A2-D is caused by mutations in the CYP21A2 gene (6p21.3). Microconversions or apparent gene conversions that cause the transfer of an inactive pseudogene (CYP21P) to the functional gene are responsible for 95% of pathogenic variations (43). Rare patients with classic CAH (SW) show a “contiguous gene syndrome”, with CAH and Ehlers–Danlos Syndrome (EDS) features, which is called “CAH-X” (44).

Essential Biochemistry/Pathophysiology

In SW CYP21A2-D, GC, and MC production is severely impaired, whereas abnormal amounts of Andr are produced, stimulated by the increased levels of ACTH. 17OHP elevation represents the hallmark of the disease, and the large majority of classic CYP21A2-D patients show basal levels of 17OHP as >300 nmol/L (>10,000 ng/dL) (45). 17OHP is converted to T and 5α-DHT, two androgens with potent activity, by the so-called “front door” pathway and directly to DHT via an alternative pathway known as “the backdoor pathway” (46, 47) (Figure 1A). The latter could lead to hyperandrogenism less responsive to GC treatment (48). 11-Keto-testosterone (11KT) is derived from 11-hydroxylation of Δ4A and T by CYP11B1 and acts as a potent androgen with a fundamental role in the pathophysiology of classic CYP21A2-D (49) (Figure 1B). It could be utilized in the future as a more precise biochemical marker of the disease (measured by means of LC/MSMS) than DHEA, Δ4A, and T (49, 50).

Neonatal Presentation

All fetuses affected by classic CAH show varying degrees of genital virilization due to exposure to intrauterine androgen excess, so that any newborn with ambiguous genitalia or in extreme cases apparently male genitalia and non-palpable gonads (45) should be suspected of having SW CAH (2, 45). Patients with 46,XX very often show a vagina that opens into a common urogenital sinus with enlarged clitoris and normal cervix, uterus, and ovaries; 46,XY children may show macrogenitosomia and genital hyperpigmentation but are generally unrecognized at birth. Sodium loss and potassium retention occur in newborns with SW CAH, due to mineralocorticoid deficiency. This may be detected biochemically from 4 to 7 days of life, but takes longer to present clinically (2nd week to 1st month of life).

Newborn Screening

In several countries, NBS has been developed for early diagnosis of CYP21A2-D by measuring 17OHP blood levels on dried blood spots. NBS is fundamental in preventing SW crises in males and male sex assignment in affected females. The diagnosis of CYP21A2-D is made when 17OHP levels are above the cutoff levels that should be elaborated and adjusted for gestational age at each screening center (51). A second-tier test on the same blood sample by LC/MSMS multi-hormonal profile could improve the positive predictive value of the CAH screening (52) and be helpful in diagnosing other rarer forms of CAH (35, 53).

Prenatal Treatment

The prenatal diagnosis of affected CAH fetuses is usually made by chorionic villous sampling at 10–12 weeks of gestation or by amniocentesis at 15–16 weeks of gestation. Treatment in utero of potentially affected CAH patients is feasible by administering dexamethasone to the mother starting from the first weeks of pregnancy, with the aim of containing adrenal hyperandrogenism by reducing ACTH hypersecretion and avoiding genital masculinization in the CYP21A2-D female fetuses (2). However, it should still be considered an experimental therapy due to potential adverse effects on both unaffected children that need to be treated until diagnosis is achieved and their mothers (45). A non-invasive method using cell-free fetal DNA in maternal plasma (NIPD at 5 weeks of gestation) could allow selective treatment in affected females only (54) but is not routinely performed due to its complexity and associated cost.

11β-Hydroxylase Deficiency (CYP11B1-D)

Epidemiology/Genetics

11-OHD is among the most common causes of CAHs in the world, after 21-OHD, and accounts for about 5% of CAH patients with a European ancestry (55) and for about 15% of CAH patients in the Muslim and Jewish Middle Eastern populations (56). The classical form of 11-OHD has an estimated frequency of 1 in 200,000 live births (57). This is caused by mutations in the CYP11B1 gene (Table 1). Approximately 130 mutations of the CYP11B1 gene have been described so far.

Essential Biochemistry

In the normal adrenals, 11β-hydroxylase is expressed in the zona fasciculata and converts 11-deoxycortisol to cortisol in response to ACTH. 11β-hydroxylase and aldosterone synthase can convert DOC into corticosterone (B). 11-OHD disrupts the synthesis of cortisol with normal production of aldosterone (1). The key steroid used in diagnosis for the classic form is elevated 11-deoxycortisol basal levels (27). Serum B, DOC, and 17-OHP are also elevated, and elevated levels of the latter can cause CYP21A2-D misdiagnosis. The urinary metabolites, such as tetrahydro-cortisone, tetrahydro-11-deoxycorticosterone, and tetrahydro-11-deoxycortisol (2), are useful for diagnosis.

Clinical Presentation and Diagnosis

The classical form is characterized by excess androgen and hypertension. ACTH excess due to cortisol deficit causes overproduction of androgens and DOC: androgens lead to virilization similar to CYP21A2-D in affected female patients (46,XX DSD); excess of DOC causes low-renin hypertension (2). Hypertension might not be apparent during the neonatal period (in about one-third of patients) due to mineralocorticoid resistance, and some patients can present with salt loss during the neonatal period, especially after the start of the GC treatment (58).

P450 Oxidoreductase Deficiency (POR-D)

Epidemiology/Genetics

POR-D was first described in 2004 (59) as a rare form of CAH. Currently, about 100 cases of POR-D have been reported worldwide with a broad clinical spectrum, and most occurring in neonates and children (60). Since 2004, some pathogenetic variants causing defective binding of co-factors and others causing altered interaction with partner proteins have been described (61). The homozygous null mutations appear to be lethal (62, 63).

Essential Biochemistry

POR is involved in the metabolism of drugs and steroid hormones because “all cytochrome P450 enzymes located in the endoplasmic reticulum get electrons for their catalytic activities from the co-factor” (61) NADPH through POR (64, 65). The main microsomal POR-dependent enzymes are involved in the biosynthesis of steroid hormones in both the adrenal cortex and gonads (CYP17A1, CYP19A1, CYP21A2, and CYP15A1), as well as in the metabolism of drugs and endogenous substrates (CYP3A4 and CYP2D6) in the liver (66–68). Several studies also suggest a possible role for POR in bone development and retinoic acid metabolism, which lead to skeletal anomalies (60).

Clinical Presentation and Diagnosis

POR-D was initially identified as a difference of sex development (DSD) with ambiguous genitalia similar to some cases of Antley–Bixler syndrome (ABS), a bone malformation syndrome due to the presence of mutations in FGFR2 (69). A recent review (60) meta-analyzed the phenotypic features in newborns with POR-D, with DSD at birth in 69% of patients (78% 46,XX and 60% 46,XY) (60). Maternal virilization during pregnancy, due to a defect in aromatase (CYP19A1) activity, is described in 21% of mothers, with the highest incidence (44.4%) when at least one of the mutations was R457H (60).

Skeletal malformations resembling ABS features were described in the 84% of PORD patients without mutations in FGFR2 (60), such as midface hypoplasia (71%), large joint synostosis (69%), craniosynostosis (65%), hand and feet malformations (61%), and bowing of the femora (21%) (63). A latent form of adrenal insufficiency rarely becomes clinically evident in the neonatal period (70–72). “Due to a very complex effect on steroid metabolism, it is preferable to diagnose PORD by performing mass spectrometry analysis of urine and blood samples” (61). Hormonal analysis is characteristic of mild to moderate increase in 17OH progesterone levels (found through neonatal screening or biochemical analysis), normal baseline ACTH, and cortisol levels with an inadequate increase in cortisol production after ACTH stimulation, normal values for renin and aldosterone, and elevated values for progesterone, corticosterone, 18OH corticosterone, 11-deoxycorticosterone (DOC), 18OH DOC, and 21-deoxycortisol (59). Low E3 and increased metabolites of Preg in urine or amniotic fluid of the mother can be useful for prenatal diagnosis (73). However, definitive diagnosis of PORD needs to be done by genetic analysis of the POR gene.

Therapeutic Approach

Glucocorticoids (GCs)

Substitutive treatment with oral hydrocortisone (10–15 mg/m²/day, divided into three daily doses) is mandatory for all classic forms of CAH presenting during the neonatal period. In CYP21A2-D and CYP11B1-D, GC administration prevents further genital virilization. Higher doses (15–30 mg/m²/day, divided into 3 or 4 daily doses) are often indicated both initially, to slow down the excessive production of potentially unfavorable metabolites (21OHD), and subsequently, as neonates and young infants often require higher doses per surface area than older children or adults. Other forms of GC are not recommended due to possible ineffectiveness (cortisone acetate) or detrimental effects on child growth (prednisolone and dexamethasone). Alawi et al. (28) suggested administering hydrocortisone at slightly higher doses (12–18 mg/m²/day) in HSD2B3-D due to the greater difficulty in suppressing androgens.

We recommend educating parents and caregivers for adrenal crisis prevention and at least doubling the dose of GC (but not MC) for situations such as febrile illness (>38.5°C) and gastroenteritis with dehydration. Parenteral hydrocortisone administration (i.v. bolus of 12.5 mg in neonates and young infants, often with glucose and saline and administered within 3–10 min; bolus repetition every 4–6 h in the first 24 h or a continuous infusion of 100 mg/m²/day) is mandatory in cases of adrenal crisis with vomiting, major surgery accompanied by general anesthesia, and major trauma.

In patients <18 months of age, close monitoring in the first 3 months of life and every 3 months thereafter is recommended (45).

Mineralocorticoids (MCs)

Fludrocortisone (0.05–0.2 mg, once or twice daily) together with sodium chloride administration during the first 6–12 months of life (5 mmol/kg/day, divided into 4–5 meals; 17 mmol or mEq = 1 g NaCl) aims to prevent adrenal crisis in StAR-D, CYP11A1-D, SW HSD2B3-D, and SW CYP21A2-D. Monitoring of K and BP levels is important for dose management.

Other Medical Treatments

In undervirilized 46,XY newborns with StAR-D, CYP11A1-D, CYP17A1-D, or POR-D reared as male, sex steroid replacement (T or DHT) might be useful during minipuberty (74). In newborns with CYP11B1-D or CYP17A1-D, if blood pressure control is not achievable by glucocorticoids alone, then appropriate antihypertensives should also be administered. Sometimes, treatment with mineralocorticoid receptor antagonists may be necessary (75). In POR-D, the supplementation of sex steroids and glucocorticoids must be based on the steroid profile of the patient, considering the possibility of impaired drug metabolism. Skeletal malformations require orthopedic management. Potential therapeutic options include the introduction of external flavin (66) and treatment with cysteamine in case of arginine to cysteamine mutations (76).

Surgical Treatment

A multidisciplinary team with competence in DSD management is recommended. In all pediatric patients with CAH, particularly minimally virilized girls (Prader I–II) and mildly undervirilized boys (EMS 7–11) (32), parents must be informed about surgical options, including delaying surgery and observation until the child is older.

Usually, the sex assignment in 46,XX newborns with CYP21A2-D or CYP11B1 is female, and genital surgery may be necessary, but the timing of the surgery remains controversial. In patients for whom early surgery is selected, vaginoplasty using urogenital mobilization is suggested, and if selected, neurovascular-sparing clitoroplasty for severe clitoromegaly is suggested (45). With early management (started <2 years of age), 46,XX patients generally have a satisfactory psychosocial outcome (77–79).

In male newborns with severe hypospadias, urological surgery is certainly indicated for functional repair (80). Although a recent review (81) found that 80% of men are satisfied with childhood hypospadias repair, it is advisable to refrain from invasive surgery that is not essential for health and to encourage patient participation and decisions in the choices regarding the sexual sphere (82).

Psychological Support

Diagnosis of classic CAH during neonatal age activates concerns and anxiety in parents related to the risk of electrolyte crises, genital ambiguity at birth, and the effects of hyperandrogenism on the brain, gender behavior, and body perception. The option of genital surgery, in case of highly virilized genitalia, represents a strong stress factor for families. Although studies in the literature show controversial results regarding the quality of life of people with CAH, case reports show that they can be psychosocial consequences related to the ambiguity of the genitalia (impaired bodily self-image, stigmatization, etc.). Therefore, we believe that psychological support is a useful complement to endocrinological and surgical management, in agreement with the Endocrine Society guidelines (45).

Author Contributions

AB and FB: conceptualization, methodology, software, CYP11A1-D, CYP21A2-D, and writing—review and editing. AC: resources. AB, FB, and RO: data curation. AB: writing—original draft preparation. RO: StAR-D and CYP17A1-D. AC and VD: 3β-HSD2D and CYP11B1-D. FB, LB, and SM: POR-D. AB and AC: supervision. All authors contributed to the article and approved the submitted version.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

All authors of this publication are members of the European Reference Network for Rare Endocrine Condition (Endo-ERN—Project ID number 739527). We would like to thank Editage (www.editage.com) for English language editing.

Abbreviations

Δ4A, Δ4-androstenedione; 11KΔ4A, 11-keto-androstenedione; 11KT, 11-keto-testosterone; 17OHP, 17α-hydroxyprogesterone; 17OHPreg, 17α-hydroxypregnenolone; Aldo, aldosterone; AMH, anti-Mullerian hormone; Andr, androgens; B, corticosterone; CAH, congenital adrenal hyperplasia; CYP11A1-D, P450 cytochrome side-chain cleavage deficiency; CYP11B1-D, 11β-hydroxylase deficiency; CYP17A1-D, 17α-hydroxylase/17-20 lyase deficiency; CYP21A2-D, 21-hydroxylase deficiency; DHEA, dehydroepiandrosterone; DHT, dihydrotestosterone; DOC, deoxycorticosterone; E1, estrone; E2, estradiol; E3, estriol; F, cortisol; EGS, External Genitalia Score; EMS, External Masculinization Score; GC, glucocorticoid; HDS3B2-D, 3β-hydroxysteroid dehydrogenase deficiency; IMM, inner mitochondrial membrane; LC/MSMS, liquid chromatography/tandem mass spectrometry; MC, mineralocorticoid; NIPD, non-invasive prenatal diagnosis; NSP, newborn screening program; OMM, outer mitochondrial membrane; POR-D, P450 oxidoreductase deficiency; Preg, pregnenolone; Prog, progesterone; S, 11-deoxycortisol; StAR-D, steroidogenic acute regulatory deficiency; SV, simple virilising; SW, salt wasting; T, testosterone; THDOC, tetrahydro-deoxycorticosterone; THS, tetrahydro-deoxycortisol; US, ultrasound.

References

1. Baronio F, Ortolano R, Menabò S, Cassio A, Baldazzi L, Di Natale V, et al. 46,XX DSD due to androgen excess in monogenic disorders of steroidogenesis: genetic, biochemical, and clinical features. Int J Mol Sci. (2019) 20:4605. doi: 10.3390/ijms20184605

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Baranowski ES, Arlt W, Idkowiak J. Monogenic disorders of adrenal steroidogenesis. Horm Res Paediatr. (2018) 89:292–310. doi: 10.1159/000488034

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Yoo H-W, Kim G-H. Molecular and clinical characterization of korean patients with congenital lipoid adrenal hyperplasia. J Pediatr Endocrinol Metab. (1998) 11:707–11. doi: 10.1515/JPEM.1998.11.6.707

PubMed Abstract | CrossRef Full Text | Google Scholar

4. Nakae J. Analysis of the steroidogenic acute regulatory protein (StAR) gene in Japanese patients with congenital lipoid adrenal hyperplasia. Hum Mol Genet. (1997) 6:571–6. doi: 10.1093/hmg/6.4.571

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Bose HS, Sugawara T, Strauss JF, Miller WL. The pathophysiology and genetics of congenital lipoid adrenal hyperplasia. N Engl J Med. (1996) 335:1870–9. doi: 10.1056/NEJM199612193352503

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Flück CE, Maret A, Mallet D, Portrat-Doyen S, Achermann JC, Leheup B, et al. A novel mutation L260P of the steroidogenic acute regulatory protein gene in three unrelated patients of swiss ancestry with congenital lipoid adrenal hyperplasia. J Clin Endocrinol Metab. (2005) 90:5304–8. doi: 10.1210/jc.2005-0874

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Kallali W, Gray E, Mehdi MZ, Lindsay R, Metherell LA, Buonocore F, et al. Long-term outcome of partial P450 side-chain cleavage enzyme deficiency in three brothers: the importance of early diagnosis. Eur J Endocrinol. (2020) 182:K15–K24. doi: 10.1530/EJE-19-0696

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Sahakitrungruang T, Tee MK, Blackett PR, Miller WL. Partial defect in the cholesterol side-chain cleavage enzyme P450scc (CYP11A1) resembling nonclassic congenital lipoid adrenal hyperplasia. J Clin Endocrinol Metab. (2011) 96:792–8. doi: 10.1210/jc.2010-1828

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Chen X, Baker BY, Abduljabbar MA, Miller WL. A Genetic isolate of congenital lipoid adrenal hyperplasia with atypical clinical findings. J Clin Endocrinol Metab. (2005) 90:835–40. doi: 10.1210/jc.2004-1323

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Gassner HL, Toppari J, Quinteiro González S, Miller WL. Near-miss apparent SIDS from adrenal crisis. J Pediatr. (2004) 145:178–83. doi: 10.1016/j.jpeds.2004.04.052

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Miller WL. Disorders in the initial steps of steroid hormone synthesis. J Steroid Biochem Mol Biol. (2017) 165:18–37. doi: 10.1016/j.jsbmb.2016.03.009

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Fujieda K, Tajima T, Nakae J, Sageshima S, Tachibana K, Suwa S, et al. Spontaneous puberty in 46,XX subjects with congenital lipoid adrenal hyperplasia. Ovarian steroidogenesis is spared to some extent despite inactivating mutations in the steroidogenic acute regulatory protein (StAR) gene. J Clin Invest. (1997) 99:1265–71. doi: 10.1172/JCI119284

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Bose HS, Pescovitz OH, Miller WL. Spontaneous feminization in a 46,XX female patient with congenital lipoid adrenal hyperplasia due to a homozygous frameshift mutation in the steroidogenic acute regulatory protein 1. J Clin Endocrinol Metab. (1997) 82:1511–5. doi: 10.1210/jcem.82.5.3962

CrossRef Full Text | Google Scholar

14. Hauffa B, Hiort O. P450 side-chain cleavage deficiency - a rare cause of congenital adrenal hyperplasia. Endocr Dev. (2011) 20:54–62. doi: 10.1159/000321215

PubMed Abstract | CrossRef Full Text | Google Scholar

15. El-Maouche D, Arlt W, Merke DP. Congenital adrenal hyperplasia. Lancet. (2017) 390:2194–210. doi: 10.1016/S0140-6736(17)31431-9

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Tajima T, Fujieda K, Kouda N, Nakae J, Miller WL. Heterozygous mutation in the cholesterol side chain cleavage enzyme (P450scc) gene in a patient with 46,XY sex reversal and adrenal insufficiency. J Clin Endocrinol Metab. (2001) 86:3820–5. doi: 10.1210/jcem.86.8.7748

PubMed Abstract | CrossRef Full Text | Google Scholar

17. Papadimitriou DT, Bothou C, Zarganis D, Karantza M, Papadimitriou A. Heterozygous mutations in the cholesterol side-chain cleavage enzyme gene (CYP11A1) can cause transient adrenal insufficiency and life-threatening failure to thrive. Hormones. (2018) 17:419–21. doi: 10.1007/s42000-018-0048-y

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev. (2011) 32:81–151. doi: 10.1210/er.2010-0013

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Miller WL. Why Nobody Has P450scc (20,22 Desmoslase) deficiency g. J Clin Endocrinol Metab. (1998) 83:1399–400. doi: 10.1210/jcem.83.4.4734-7

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Hiort O, Holterhus P-M, Werner R, Marschke C, Hoppe U, Partsch C-J, et al. Homozygous disruption of P450 side-chain cleavage (CYP11A1) is associated with prematurity, complete 46,XY sex reversal, and severe adrenal failure. J Clin Endocrinol Metab. (2005) 90:538–41. doi: 10.1210/jc.2004-1059

PubMed Abstract | CrossRef Full Text | Google Scholar

21. Kim CJ, Lin L, Huang N, Quigley CA, AvRuskin TW, Achermann JC, et al. Severe combined adrenal and gonadal deficiency caused by novel mutations in the cholesterol side chain cleavage enzyme, P450scc. J Clin Endocrinol Metab. (2008) 93:696–702. doi: 10.1210/jc.2007-2330

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Tee MK, Abramsohn M, Loewenthal N, Harris M, Siwach S, Kaplinsky A, et al. Varied clinical presentations of seven patients with mutations in CYP11A1 encoding the cholesterol side-chain cleavage enzyme, P450scc. J Clin Endocrinol Metab. (2013) 98:713–20. doi: 10.1210/jc.2012-2828

PubMed Abstract | CrossRef Full Text | Google Scholar

23. Voutilainen R, Miller WL. Developmental expression of genes for the stereoidogenic enzymes P450scc (20,22-Desmolase), P450cl7 (17αHydroxylase/17,20-Lyase), and P450c21 (21-Hydroxylase) in the human fetus*. J Clin Endocrinol Metab. (1986) 63:1145–50. doi: 10.1210/jcem-63-5-1145

PubMed Abstract | CrossRef Full Text | Google Scholar

24. Rubtsov P, Karmanov M, Sverdlova P, Spirin P, Tiulpakov A. A novel homozygous mutation in CYP11A1 gene is associated with late-onset adrenal insufficiency and hypospadias in a 46,XY patient. J Clin Endocrinol Metab. (2009) 94:936–9. doi: 10.1210/jc.2008-1118

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Parajes S, Chan AO, But WM, Rose IT, Taylor AE, Dhir V., et al. Delayed diagnosis of adrenal insufficiency in a patient with severe penoscrotal hypospadias due to two novel P450 side-change cleavage enzyme (CYP11A1) mutations (p.R360W; p.R405X). Eur J Endocrinol. (2012) 167:881–5. doi: 10.1530/EJE-12-0450

PubMed Abstract | CrossRef Full Text | Google Scholar

26. Abdulhadi-Atwan M, Jean A, Chung WK, Meir K, Ben Neriah Z, Stratigopoulos G, et al. Role of a founder c.201_202delCT mutation and new phenotypic features of congenital lipoid adrenal hyperplasia in palestinians. J Clin Endocrinol Metab. (2007) 92:4000–8. doi: 10.1210/jc.2007-1306

PubMed Abstract | CrossRef Full Text | Google Scholar

27. Miller WL. MECHANISMS IN ENDOCRINOLOGY: Rare defects in adrenal steroidogenesis. Eur J Endocrinol. (2018) 179:R125–R41. doi: 10.1530/EJE-18-0279

PubMed Abstract | CrossRef Full Text | Google Scholar

28. Al Alawi AM, Nordenström A, Falhammar H. Clinical perspectives in congenital adrenal hyperplasia due to 3β-hydroxysteroid dehydrogenase type 2 deficiency. Endocrine. (2019) 63:407–21. doi: 10.1007/s12020-018-01835-3

PubMed Abstract | CrossRef Full Text | Google Scholar

29. Simard J, Moisan AM, Morel Y. Congenital adrenal hyperplasia due to 3beta-hydroxysteroid dehydrogenase/Delta(5)-Delta(4) isomerase deficiency. Semin Reprod Med. (2002) 20:255–76. doi: 10.1055/s-2002-35373

CrossRef Full Text | Google Scholar

30. Guran T, Kara C, Yildiz M, Bitkin EC, Haklar G, Lin J-C, et al. Revisiting classical 3β-hydroxysteroid dehydrogenase 2 deficiency: lessons from 31 pediatric cases. J Clin Endocrinol Metab. (2020) 105:dgaa022. doi: 10.1210/clinem/dgaa022

PubMed Abstract | CrossRef Full Text | Google Scholar

31. van der Straaten S, Springer A, Zecic A, Hebenstreit D, Tonnhofer U, Gawlik A, et al. The external genitalia score (EGS): a European multicenter validation study. J Clin Endocrinol Metab. (2019) 105:dgz142. doi: 10.1210/clinem/dgz142

PubMed Abstract | CrossRef Full Text | Google Scholar

32. Ahmed SF, Khwaja O, Hughes IA. The role of a clinical score in the assessment of ambiguous genitalia. BJU Int. (2000) 85:120–4. doi: 10.1046/j.1464-410x.2000.00354.x

PubMed Abstract | CrossRef Full Text | Google Scholar

33. Prader A. [Perfect male external genital development and salt-loss syndrome in girls with congenital adrenogenital syndrome]. Helv Paediatr Acta. (1958) 13:5–14.

PubMed Abstract | Google Scholar

34. Benkert AR, Young M, Robinson D, Hendrickson C, Lee PA, Strauss KA. Severe salt-losing 3β-hydroxysteroid dehydrogenase deficiency: treatment and outcomes of HSD3B2 c.35G>A homozygotes. J Clin Endocrinol Metab. (2015) 100:E1105–E15. doi: 10.1210/jc.2015-2098

PubMed Abstract | CrossRef Full Text | Google Scholar

35. Nordenström A, Forest MG, Wedell A. A case of 3beta-hydroxysteroid dehydrogenase type II (HSD3B2) deficiency picked up by neonatal screening for 21-hydroxylase deficiency: difficulties and delay in etiologic diagnosis. Horm Res. (2007) 68:204–8. doi: 10.1159/000102593

PubMed Abstract | CrossRef Full Text | Google Scholar

36. Levy-Shraga Y, Pinhas-Hamiel O. High 17-hydroxyprogesterone level in newborn screening test for congenital adrenal hyperplasia. BMJ Case Rep. (2016) 2016:bcr2015213939. doi: 10.1136/bcr-2015-213939

PubMed Abstract | CrossRef Full Text | Google Scholar

37. Araújo VGB de, Oliveira RS de, Gameleira KPD, Cruz CB, Lofrano-Porto A. 3β-hydroxysteroid dehydrogenase type II deficiency on newborn screening test. Arq Bras Endocrinol Metabol. (2014) 58:650–5. doi: 10.1590/0004-2730000003098

PubMed Abstract | CrossRef Full Text | Google Scholar

38. Krone N, Hughes BA, Lavery GG, Stewart PM, Arlt W, Shackleton CHL. Gas chromatography/mass spectrometry (GC/MS) remains a pre-eminent discovery tool in clinical steroid investigations even in the era of fast liquid chromatography tandem mass spectrometry (LC/MS/MS). J Steroid Biochem Mol Biol. (2010) 121:496–504. doi: 10.1016/j.jsbmb.2010.04.010

PubMed Abstract | CrossRef Full Text | Google Scholar

39. Breder ISS, Garmes HM, Mazzola TN, Maciel-Guerra AT, de Mello MP, Guerra-Júnior G. Three new Brazilian cases of 17α-hydroxylase deficiency: clinical, molecular, hormonal, and treatment features. J Pediatr Endocrinol Metab. (2018) 31:937–42. doi: 10.1515/jpem-2017-0521

PubMed Abstract | CrossRef Full Text | Google Scholar

40. Kim SM, Rhee JH. A case of 17 alpha-hydroxylase deficiency. Clin Exp Reprod Med. (2015) 42:72–6. doi: 10.5653/cerm.2015.42.2.72

PubMed Abstract | CrossRef Full Text | Google Scholar

41. Chormanski D, Muzio MR. C 17 hydroxylase deficiency. In StatPearls. Treasure Island, FL: StatPearls Publishing. Available online at: http://www.ncbi.nlm.nih.gov/books/NBK546644/ (accessed March 28, 2020).

PubMed Abstract | Google Scholar

42. Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet Lond Engl. (2005) 365:2125–36. doi: 10.1016/S0140-6736(05)66736-0

PubMed Abstract | CrossRef Full Text | Google Scholar

43. Hughes IA, Houk C, Ahmed SF, Lee PA, LWPES Consensus Group, ESPE Consensus Group. Consensus statement on management of intersex disorders. Arch Dis Child. (2006) 91:554–63. doi: 10.1136/adc.2006.098319

PubMed Abstract | CrossRef Full Text | Google Scholar

44. Miller WL, Merke DP. Tenascin-X, Congenital adrenal hyperplasia, and the CAH-X syndrome. Horm Res Paediatr. (2018) 89:352–61. doi: 10.1159/000481911

PubMed Abstract | CrossRef Full Text | Google Scholar

45. Speiser PW, Arlt W, Auchus RJ, Baskin LS, Conway GS, Merke DP, et al. Congenital adrenal hyperplasia due to steroid 21-Hydroxylase deficiency: an endocrine society* clinical practice guideline. J Clin Endocrinol Metab. (2018) 103:4043–88. doi: 10.1210/jc.2018-01865

PubMed Abstract | CrossRef Full Text | Google Scholar

46. Swart AC, Schloms L, Storbeck K-H, Bloem LM, Toit Td, Quanson JL, et al. 11β-Hydroxyandrostenedione, the product of androstenedione metabolism in the adrenal, is metabolized in LNCaP cells by 5α-reductase yielding 11β-hydroxy-5α-androstanedione. J Steroid Biochem Mol Biol. (2013) 138:132–42. doi: 10.1016/j.jsbmb.2013.04.010

PubMed Abstract | CrossRef Full Text | Google Scholar

47. O'Shaughnessy PJ, Antignac JP, Le Bizec B, Morvan M-L, Svechnikov K, Söder O, et al. Alternative (backdoor) androgen production and masculinization in the human fetus. PLOS Biol. (2019) 17:e3000002. doi: 10.1371/journal.pbio.3000002

PubMed Abstract | CrossRef Full Text | Google Scholar

48. Jones CM, Mallappa A, Reisch N, Nikolaou N, Krone N, Hughes BA, et al. Modified-release and conventional glucocorticoids and diurnal androgen excretion in congenital adrenal hyperplasia. J Clin Endocrinol Metab. (2017) 102:1797–806. doi: 10.1210/jc.2016-2855

PubMed Abstract | CrossRef Full Text | Google Scholar

49. Kamrath C, Wettstaedt L, Boettcher C, Hartmann MF, Wudy SA. Androgen excess is due to elevated 11-oxygenated androgens in treated children with congenital adrenal hyperplasia. J Steroid Biochem Mol Biol. (2018) 178:221–8. doi: 10.1016/j.jsbmb.2017.12.016

PubMed Abstract | CrossRef Full Text | Google Scholar

50. Bacila I, Adaway J, Hawley J, Mahdi S, Krone R, Patel L, et al. Measurement of salivary adrenal-specific androgens as biomarkers of therapy control in 21-hydroxylase deficiency. J Clin Endocrinol Metab. (2019) 104:6417–29. doi: 10.1210/jc.2019-00031

PubMed Abstract | CrossRef Full Text | Google Scholar

51. Balsamo A, Cacciari E, Piazzi S, Cassio A, Bozza D, Pirazzoli P, et al. Congenital adrenal hyperplasia: neonatal mass screening compared with clinical diagnosis only in the Emilia-Romagna region of Italy, 1980-1995. Pediatrics. (1996) 98:362–7.

PubMed Abstract | Google Scholar

52. Choi R, Park H-D, Oh HJ, Lee K, Song J, Lee S-Y. Dried blood spot multiplexed steroid profiling using liquid chromatography tandem mass spectrometry in korean neonates. Ann Lab Med. (2019) 39:263. doi: 10.3343/alm.2019.39.3.269

PubMed Abstract | CrossRef Full Text

53. Güran T, Tezel B, Gürbüz F, Selver Eklioglu B, Hatipoglu N, Kara C, et al. Neonatal screening for congenital adrenal hyperplasia in turkey: a pilot study with 38,935 infants. J Clin Res Pediatr Endocrinol. (2019) 11:13–3. doi: 10.4274/jcrpe.galenos.2018.2018.0117

PubMed Abstract | CrossRef Full Text | Google Scholar

54. New MI, Tong YK, Yuen T, Jiang P, Pina C, Chan KCA, et al. Noninvasive prenatal diagnosis of congenital adrenal hyperplasia using cell-free fetal DNA in maternal plasma. J Clin Endocrinol Metab. (2014) 99:E1022–E30. doi: 10.1210/jc.2014-1118

PubMed Abstract | CrossRef Full Text | Google Scholar

55. Chabraoui L, Abid F, Menassa R, Gaouzi A, El Hessni A, Morel Y. Three novel CYP11B1 mutations in congenital adrenal hyperplasia due to steroid 11beta-hydroxylase deficiency in a moroccan population. Horm Res Paediatr. (2010) 74:182–9. doi: 10.1159/000281417

CrossRef Full Text | Google Scholar

56. Zachmann M, Tassinari D, Prader A. Clinical and biochemical variability of congenital adrenal hyperplasia due to llβ-hydroxylase deficiency, a study of 25 patients*. J Clin Endocrinol Metab. (1983) 56:222–9. doi: 10.1210/jcem-56-2-222

PubMed Abstract | CrossRef Full Text | Google Scholar

57. Menabò S, Polat S, Baldazzi L, Kulle AE, Holterhus P-M, Grötzinger J, et al. Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency: functional consequences of four CYP11B1 mutations. Eur J Hum Genet. (2014) 22:610–6. doi: 10.1038/ejhg.2013.197

PubMed Abstract | CrossRef Full Text | Google Scholar

58. Holcombe JH, Keenan BS, Nichols BL, Kirkland RT, Clayton GW. Neonatal salt loss in the hypertensive form of congenital adrenal hyperplasia. Pediatrics. (1980) 65:777–81.

PubMed Abstract | Google Scholar

59. Flück CE, Tajima T, Pandey AV, Arlt W, Okuhara K, Verge CF, et al. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet. (2004) 36:228–30. doi: 10.1038/ng1300

PubMed Abstract | CrossRef Full Text | Google Scholar

60. Dean B, Chrisp GL, Quartararo M, Maguire AM, Hameed S, King BR, et al. P450 oxidoreductase deficiency: a systematic review and meta-analysis of genotypes, phenotypes, and their relationships. J Clin Endocrinol Metab. (2020) 105:e42–e52. doi: 10.1210/clinem/dgz255

PubMed Abstract | CrossRef Full Text | Google Scholar

61. Burkhard FZ, Parween S, Udhane SS, Flück CE, Pandey AV. P450 Oxidoreductase deficiency: analysis of mutations and polymorphisms. J Steroid Biochem Mol Biol. (2017) 165:38–50. doi: 10.1016/j.jsbmb.2016.04.003

PubMed Abstract | CrossRef Full Text | Google Scholar

62. Fukami M, Nishimura G, Homma K, Nagai T, Hanaki K, Uematsu A, et al. Cytochrome P450 oxidoreductase deficiency: identification and characterization of biallelic mutations and genotype-phenotype correlations in 35 Japanese patients. J Clin Endocrinol Metab. (2009) 94:1723–31. doi: 10.1210/jc.2008-2816

PubMed Abstract | CrossRef Full Text | Google Scholar

63. Krone N, Reisch N, Idkowiak J, Dhir V, Ivison HE, Hughes BA, et al. Genotype-phenotype analysis in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. J Clin Endocrinol Metab. (2012) 97:E257–67. doi: 10.1210/jc.2011-0640

PubMed Abstract | CrossRef Full Text | Google Scholar

64. Pandey AV, Flück CE. NADPH P450 oxidoreductase: Structure, function, and pathology of diseases. Pharmacol Ther. (2013) 138:229–54. doi: 10.1016/j.pharmthera.2013.01.010

PubMed Abstract | CrossRef Full Text | Google Scholar

65. Riddick DS, Ding X, Wolf CR, Porter TD, Pandey AV, Zhang Q-Y, et al. NADPH-cytochrome P450 oxidoreductase: roles in Physiology, pharmacology, and toxicology. Drug Metab Dispos. (2013) 41:12–23. doi: 10.1124/dmd.112.048991

PubMed Abstract | CrossRef Full Text | Google Scholar

66. Nicolo C, Flück CE, Mullis PE, Pandey AV. Restoration of mutant cytochrome P450 reductase activity by external flavin. Mol Cell Endocrinol. (2010) 321:245–52. doi: 10.1016/j.mce.2010.02.024

PubMed Abstract | CrossRef Full Text | Google Scholar

67. Flück CE, Mullis PE, Pandey AV. Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism. Biochem Biophys Res Commun. (2010) 401:149–53. doi: 10.1016/j.bbrc.2010.09.035

PubMed Abstract | CrossRef Full Text | Google Scholar

68. Ono T, Bloch K. Solubilization and partial characterization of rat liver squalene epoxidase. J Biol Chem. (1975) 250:1571–9.

PubMed Abstract | Google Scholar

69. Antley R, Bixler D. Trapezoidocephaly, midfacial hypoplasia and cartilage abnormalities with multiple synostoses and skeletal fractures. Birth Defects Orig Artic Ser. (1975) 11:397–401.

PubMed Abstract | Google Scholar

70. Idkowiak J, O'Riordan S, Reisch N, Malunowicz EM, Collins F, Kerstens MN, et al. Pubertal presentation in seven patients with congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. J Clin Endocrinol Metab. (2011) 96:E453–E62. doi: 10.1210/jc.2010-1607

PubMed Abstract | CrossRef Full Text | Google Scholar

71. Papadakis GE, Dumont A, Bouligand J, Chasseloup F, Raggi A, Catteau-Jonard S, et al. Non-classic cytochrome P450 oxidoreductase deficiency strongly linked with menstrual cycle disorders and female infertility as primary manifestations. Hum Reprod. (2020) 35:939–49. doi: 10.1093/humrep/deaa020

PubMed Abstract | CrossRef Full Text | Google Scholar

72. Bonamichi BDSF, Santiago SLM, Bertola DR, Kim CA, Alonso N, Mendonca BB, et al. Long-term follow-up of a female with congenital adrenal hyperplasia due to P450-oxidoreductase deficiency. Arch Endocrinol Metab. (2016) 60:500–4. doi: 10.1590/2359-3997000000213

PubMed Abstract | CrossRef Full Text | Google Scholar

73. Shackleton C, Marcos J, Arlt W, Hauffa BP. Prenatal diagnosis of P450 oxidoreductase deficiency (ORD): a disorder causing low pregnancy estriol, maternal and fetal virilization, and the Antley-Bixler syndrome phenotype. Am J Med Genet. (2004) 129A:105–12. doi: 10.1002/ajmg.a.30171

PubMed Abstract | CrossRef Full Text | Google Scholar

74. Xu D, Lu L, Xi L, Cheng R, Pei Z, Bi Y, et al. Efficacy and safety of percutaneous administration of dihydrotestosterone in children of different genetic backgrounds with micropenis. J Pediatr Endocrinol Metab. (2017) 30:1285–91. doi: 10.1515/jpem-2016-0400

PubMed Abstract | CrossRef Full Text | Google Scholar

75. Geley S, Kapelari K, Jöhrer K, Peter M, Glatzl J, Vierhapper H, et al. CYP11B1 mutations causing congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. J Clin Endocrinol Metab. (1996) 81:2896–901. doi: 10.1210/jcem.81.8.8768848

PubMed Abstract | CrossRef Full Text | Google Scholar

76. Inauen C, Rüfenacht V, Pandey AV, Hu L, Blom H, Nuoffer J-M, et al. Effect of cysteamine on mutant ASL proteins with cysteine for arginine substitutions. Mol Diagn Ther. (2016) 20:125–33. doi: 10.1007/s40291-015-0182-z

PubMed Abstract | CrossRef Full Text | Google Scholar

77. Suorsa KI, Mullins AJ, Tackett AP, Scott Reyes KJ, Austin P, Baskin L, et al. Characterizing early psychosocial functioning of parents of children with moderate to severe genital ambiguity due to disorders of sex development. J Urol. (2015) 194:1737–42. doi: 10.1016/j.juro.2015.06.104

PubMed Abstract | CrossRef Full Text | Google Scholar

78. Almasri J, Zaiem F, Rodriguez-Gutierrez R, Tamhane SU, Iqbal AM, Prokop LJ, et al. Genital reconstructive surgery in females with congenital adrenal hyperplasia: a systematic review and meta-analysis. J Clin Endocrinol Metab. (2018) 103:4089–96. doi: 10.1210/jc.2018-01863

PubMed Abstract | CrossRef Full Text | Google Scholar

79. Razzaghy-Azar M, Karimi S, Shirazi E. Gender identity in patients with congenital adrenal hyperplasia. Int J Endocrinol Metab. (2017) 15:e12537. doi: 10.5812/ijem.12537

PubMed Abstract | CrossRef Full Text | Google Scholar

80. Snodgrass W, Bush N. Is distal hypospadias repair mostly a cosmetic operation? J Pediatr Urol. (2018) 14:339–40. doi: 10.1016/j.jpurol.2018.06.004

PubMed Abstract | CrossRef Full Text | Google Scholar

81. Tack LJW, Springer A, Riedl S, Tonnhofer U, Weninger J, Hiess M, et al. Psychosexual outcome, sexual function, and long-term satisfaction of adolescent and young adult men after childhood hypospadias repair. J Sex Med. (2020) 17:1665–75. doi: 10.1016/j.jsxm.2020.04.002

PubMed Abstract | CrossRef Full Text | Google Scholar

82. Roen K, Hegarty P. Shaping parents, shaping penises: How medical teams frame parents' decisions in response to hypospadias. Br J Health Psychol. (2018) 23:967–81. doi: 10.1111/bjhp.12333

PubMed Abstract | CrossRef Full Text | Google Scholar